A Phase Ib, Open-Label Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Trastuzumab Emtansine or With Trastuzumab and Pertuzumab (With and Without Docetaxel) in Patients With HER2-Positive BReast Cancer and Atezolizumab With Doxorubicin and Cyclophosphamide in HER2-Negative Breast Cancer

• Men or women

• Metastatic or locally advanced or recurrent breast cancer

• If HER2 negative, no more than two prior chemotherapy lines in metastatic disease and no prior anthracycline

• Must have prior treatment with a taxane and trastuzumab in any setting

  • If treated in 2nd line or later, must have progressive disease since last regimen

  • If treated in 1st line metastatic, must have progression within 6 months of completing adjuvant therapy

• Tumor specimen must be obtained after the most recent breast cancer systemic therapy

• ECOG PS 0-2

• Measurable disease

• LVEF >50% by ECHO or MUGA

• Adequate labs

• No known CNS disease except for treated asymptomatic supratentorial mets with no need for active steroids

• No leptomeningeal disease

• No grade 2 or higher peripheral neuropathy
• No history of autoimmune disease or need for current immunosuppressants
• No HVB/HCV/HIV

Primary- DLTs, Safety; Secondary- Anti-therapeutic antibody, VS results, number of cycles received, PK